Posted by Michael Wonder on 03 Oct 2022
Calithera receives FDA fast track designation for sapanisertib for the treatment of NRF2 mutated squamous lung cancer
3 October 2022 - Enrollment on-going in Phase 2 study evaluating sapanisertib, a dual mTORC1/2 inhibitor, in patients with squamous non-small-cell lung cancer harbouring a NRF2 mutation.
Calithera Biosciences today announced that the US FDA has granted fast track designation for the company’s investigational mTORC 1/2 inhibitor sapanisertib (CB-228) for the treatment of adult patients with unresectable or metastatic squamous non-small cell lung cancer whose tumours have a mutation in nuclear factor erythroid 2-related factor (NFE2L2, also called NRF2) and who have received prior platinum-based chemotherapy and immune checkpoint inhibitor therapy.
